Navigantis has recently revealed the successful execution of initial neurovascular clinical procedures using its Vasco interventional robotic system. This innovative platform, developed by the Miami-headquartered company, specifically caters to individuals suffering from neurovascular ailments, such as acute ischemic stroke. Initial human trials took place in 2022, during which the preceding model efficiently executed robotic liver tumor embolizations.
According to Navigantis, the neurovascular interventional robotic study encompasses patients receiving diagnostic cerebral angiograms and treatments like brain tumor embolization and mechanical thrombectomy for ischemic stroke. The research is spearheaded by Dong Joon Kim at Severance Hospital in Seoul, South Korea.
“The success of these initial robotic procedures signifies a pivotal step in advancing treatment of intricate neurovascular disorders,” expressed Kim.
Navigantis aims to equip healthcare providers with tools for delivering “unmatched neurovascular care” and envisions establishing “a new frontier in surgical robotics.” Mor Dayan, Navigantis’ CEO, indicated that these pioneering clinical cases represent a considerable progress point for the organization.
Dayan commented, “The Vasco robotic system has the potential to revolutionize complex and urgent neurovascular interventions, aiming to enhance patient outcomes and procedural efficiency.” He emphasized that this is among the primary milestones toward enabling robotic telesurgery for stroke cases, which could significantly shorten response times and improve access to vital emergency care.